NVO Stock Summary and Trading Ideas (Novo Nordisk A/S | NYSE:NVO)

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk A/S trades on the NYSE stock market under the symbol NVO.

As of February 4, 2025, NVO stock price declined to $82.61 with 7,291,825 million shares trading.

NVO has a beta of 1.06, meaning it tends to be more sensitive to market movements. NVO has a correlation of 0.13 to the broad based SPY ETF.

NVO has a market cap of $367.05 billion. This is considered a Mega Cap stock.

Last quarter Novo Nordisk A/S reported $11 billion in Revenue and $.90 earnings per share. This beat revenue expectation by $14 million and exceeded earnings estimates by $.02.

In the last 3 years, NVO traded as high as $148.15 and as low as $47.38.

The top ETF exchange traded funds that NVO belongs to (by Net Assets): AVDE, FVD, PPH, NUGO, DFIC.

NVO has underperformed the market in the last year with a return of -26.1%, while the SPY ETF gained +23.1%. In the last 3 month period, NVO fell short of the market, returning -26.2%, while SPY returned +5.7%. However, in the most recent 2 weeks NVO has outperformed the stock market by returning +5.0%, while SPY returned +0.7%.

NVO support price is $80.72 and resistance is $84.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVO shares will trade within this expected range on the day.